相关实验视频

Updated: Jun 3, 2025

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

抗体-药物结合物的潜力,在扩散大B细胞淋巴瘤的有效治疗中

Gulrayz Ahmed¹, Mehdi Hamadani¹, Taha Al-Juhaishi²

¹Division of Hematology & Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.

Expert opinion on biological therapy

|January 11, 2025

概括

抗体-药物合物 (ADCs) 正在彻底改变血液癌症治疗. 隆卡斯图西马布特西林和波拉图祖马布维多丁为扩散性大B细胞淋巴瘤 (DLBCL) 提供了有效的选择,具有可管理的安全性.

科学领域:

在瘤学瘤学.
血液学血液学血液学
药理学药理学是指药理学的学科.

背景情况:

抗体与药物联合体 (ADC) 是抗癌疗法的重大进展.
抗癌剂利用细胞毒性有效载荷的向向癌细胞的传递,提高了有效性和安全性.
扩散性大B细胞淋巴瘤 (DLBCL) 是一种血液性恶性瘤,其中ADCs已经显示出显著的影响.

研究的目的:

审查loncastuximab tesirine和polatuzumab vedotin在DLBCL治疗中的疗效和安全性.
讨论在临床开发中新兴的基于ADC的组合疗法和新的ADC结构.

主要方法:

在DLBCL中对已批准的ADC发表的疗效和安全数据的审查.
对新的ADC疗法和组合正在进行的临床试验的分析.

主要成果:

隆卡斯图西马布特西林和波拉图祖马布维多丁已获得批准,是DLBCL的有效治疗方法.
波拉图祖马布维多丁适用于一线和复发性/耐火性DLBCL.
隆卡斯图西马布特西林已被批准用于复发DLBCL,证明了可以容忍的安全性.

结论:

ADCs已经大大改善了DLBCL患者的结果.
目前的ADC提供了有效性和安全性的良好平衡.
许多新的ADC和组合策略正在调查中,有望在DLBCL管理方面取得进一步进展.

关键词:

扩散大的B细胞淋巴瘤.伦卡斯图西马布特西林 (Loncastuximab tesirine) 是一种药物.波拉图祖马布 (Polatuzumab) 是一种可见的药物.抗体与药物结合物的结合物.药物开发是药物的发展.一个单克隆抗体.非霍奇金淋巴瘤的非霍奇金淋巴瘤.

更多相关视频

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

B Cell Activation and Differentiation

B Cell Activation and Differentiation

The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.